122 259

Cited 42 times in

Molecular diagnosis for personalized target therapy in gastric cancer

DC Field Value Language
dc.contributor.author조재용-
dc.date.accessioned2018-05-10T06:42:21Z-
dc.date.available2018-05-10T06:42:21Z-
dc.date.issued2013-
dc.identifier.issn2093-582X-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/158467-
dc.description.abstractGastric cancer is the second leading cause of cancer-related deaths worldwide. In advanced and metastatic gastric cancer, the conventional chemotherapy with limited efficacy shows an overall survival period of about 10 months. Patient specific and effective treatments known as personalized cancer therapy is of significant importance. Advances in high-throughput technologies such as microarray and next generation sequencing for genes, protein expression profiles and oncogenic signaling pathways have reinforced the discovery of treatment targets and personalized treatments. However, there are numerous challenges from cancer target discoveries to practical clinical benefits. Although there is a flood of biomarkers and target agents, only a minority of patients are tested and treated accordingly. Numerous molecular target agents have been under investigation for gastric cancer. Currently, targets for gastric cancer include the epidermal growth factor receptor family, mesenchymal-epithelial transition factor axis, and the phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathways. Deeper insights of molecular characteristics for gastric cancer has enabled the molecular classification of gastric cancer, the diagnosis of gastric cancer, the prediction of prognosis, the recognition of gastric cancer driver genes, and the discovery of potential therapeutic targets. Not only have we deeper insights for the molecular diversity of gastric cancer, but we have also prospected both affirmative potentials and hurdles to molecular diagnostics. New paradigm of transdisciplinary team science, which is composed of innovative explorations and clinical investigations of oncologists, geneticists, pathologists, biologists, and bio-informaticians, is mandatory to recognize personalized target therapy.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherKorean Gastric Cancer Association-
dc.relation.isPartOfJOURNAL OF GASTRIC CANCER-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titleMolecular diagnosis for personalized target therapy in gastric cancer-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Internal Medicine-
dc.contributor.googleauthorJae Yong Cho-
dc.identifier.doi10.5230/jgc.2013.13.3.129-
dc.contributor.localIdA03899-
dc.relation.journalcodeJ01415-
dc.identifier.eissn2093-5641-
dc.identifier.pmid24156032-
dc.subject.keywordStomach neoplasms-
dc.subject.keywordTherapeutics-
dc.subject.keywordBiological markers-
dc.subject.keywordGene expression-
dc.subject.keywordSequence analysis-
dc.contributor.alternativeNameCho, Jae Yong-
dc.contributor.affiliatedAuthorCho, Jae Yong-
dc.citation.volume13-
dc.citation.number3-
dc.citation.startPage129-
dc.citation.endPage135-
dc.identifier.bibliographicCitationJOURNAL OF GASTRIC CANCER, Vol.13(3) : 129-135, 2013-
dc.identifier.rimsid42466-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.